Regulatory Affairs

Public Disclosure Protocol

We adhere to a Public Disclosure Protocol with the objectives of providing information on the licensed activities to persons living near the site, fostering public awareness and providing channels for community members to share issues and concerns related to our licensed facilities.

The Public Disclosure Protocol is available as a PDF here.

The Public Disclosure Protocol describes how we communicate with our target audience.

Based on this protocol, BWXT Medical commits to:
  • Consulting with stakeholders to determine the type of information, and method for information sharing regarding this Public Disclosure Protocol
  • Maintaining two-way communication channels with the target audience to understand and address comments, questions and concerns
  • Providing reporting on its website within 48 hours of unusual operational events with the potential for offsite consequences
  • Providing timely reporting on its website within 48 hours of environmental events that trigger notification of the CNSC under Section 29 of the General Nuclear Safety and Control Regulations
  • Providing information to the target audience through BWXT Medical’s website and/or other Public Information Program activities, about significant operational changes or expansions that require an environmental assessment or amendments to the facility licence;
  • Posting environmental monitoring results (relevant sections of Annual Compliance Reports) on its website
  • Posting any transport incidents reportable under the CNSC Packaging & Transport of Nuclear Substances Regulations
  • Posting planned and unplanned significant interruptions of facility operations resulting in significant disruption of customer isotope supply;
  • Posting this Public Disclosure Protocol on the BWXT Medical website.

Any proposed changes to the Public Disclosure Protocol are reviewed and approved prior to implementation.

Our Public Disclosure Protocol does not prescribe the release of sensitive information, such as security related information and trade secrets or scientific, technical, commercial, financial or labour relations information.


Public Disclosures To Date

2024 BWXT Medical Public Disclosures
  • 2023 
    • Minor damages to packages during transport. In 2023, there were four (4) instances of damaged packages during transportation. In all cases the damage was minor, with no impact to the integrity of radioactive product. There was no impact to health, safety or the environment.
  • 2022
    • Minor damages to packages during transport In 2022, there were three (3) instances of damaged packages during transportation to customers. In all cases the damage was minor, with no impact to the integrity of the radioactive product. There was no impact to health, safety or the environment.

Type A packages containing Y-90 were damaged during transport on the following dates:


CNSC License Documentation

On December 17, 2018, we submitted an application to the Canadian Nuclear Safety Commission (CNSC) to request issuance of our own Class IB Licence for a period of 10 years.

On October 15, 2021, the CNSC issued a news release on their Record of Decision for our licence application. The news release can be viewed here. The licence is valid until October 31, 2031.

If you have any questions about licensing or our operations, please contact us at [email protected] or 1.833.657.4565.


This Website Uses Cookies.

We use cookies to give you the best user experience. No personal information is collected in this process.